Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Sequential Dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Human Post-Menopausal Female Volunteers

NCT06467201 is registered in ClinicalTrials.gov with Amneal Pharmaceuticals, LLC as lead sponsor.

NCT NCT06467201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06467201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Sequential Dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Human Post-Menopausal Female Volunteers
Lead sponsor
Amneal Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Completed
Start date
June 3, 2024
Completion date
March 12, 2025
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy postmenopausal women